- Home
- OBIO vs NKTR Comparison
OBIO vs NKTR Comparison
Compare OBIO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- NKTR
- Stock Information
- Founded
- OBIO 2017
- NKTR 1990
- Country
- OBIO United States
- NKTR United States
- Employees
- OBIO N/A
- NKTR N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- NKTR Health Care
- Exchange
- OBIO Nasdaq
- NKTR Nasdaq
- Market Cap
- OBIO 151.3M
- NKTR 160.4M
- IPO Year
- OBIO N/A
- NKTR 1994
- Fundamental
- Price
- OBIO $2.85
- NKTR $0.64
- Analyst Decision
- OBIO Strong Buy
- NKTR Strong Buy
- Analyst Count
- OBIO 5
- NKTR 6
- Target Price
- OBIO $15.00
- NKTR $4.92
- AVG Volume (30 Days)
- OBIO 69.1K
- NKTR 2.8M
- Earning Date
- OBIO 05-12-2025
- NKTR 05-08-2025
- Dividend Yield
- OBIO N/A
- NKTR N/A
- EPS Growth
- OBIO N/A
- NKTR N/A
- EPS
- OBIO N/A
- NKTR N/A
- Revenue
- OBIO $2,638,000.00
- NKTR $98,427,000.00
- Revenue This Year
- OBIO $27.37
- NKTR N/A
- Revenue Next Year
- OBIO $42.68
- NKTR N/A
- P/E Ratio
- OBIO N/A
- NKTR N/A
- Revenue Growth
- OBIO N/A
- NKTR 9.21
- 52 Week Low
- OBIO $2.49
- NKTR $0.43
- 52 Week High
- OBIO $8.87
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- OBIO 36.86
- NKTR 45.85
- Support Level
- OBIO $2.75
- NKTR $0.43
- Resistance Level
- OBIO $3.26
- NKTR $0.68
- Average True Range (ATR)
- OBIO 0.48
- NKTR 0.08
- MACD
- OBIO -0.01
- NKTR 0.01
- Stochastic Oscillator
- OBIO 16.82
- NKTR 72.41
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.